Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Alzheimer's Dementia (AD)

Tundra lists 2 Alzheimer's Dementia (AD) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07757204

An Open-label Long-term Safety Study of Buntanetap in Participants With AD

This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.

Gender: All

Ages: 55 Years - Any

Updated: 2026-08-19

Alzheimer's Dementia (AD)
ENROLLING BY INVITATION

NCT07594665

Expanding Access to Cognitive Health Biomarker Testing at Home

The goal of this observational study is to learn whether at-home blood biomarker testing for Alzheimer's disease risk is feasible and acceptable in older adults with cognitive concerns. The main questions it aims to answer are: * Can older adults with subjective cognitive concerns or possible mild cognitive impairment successfully complete a fully remote workflow that includes at-home capillary blood collection, overnight shipping, central laboratory analysis of phosphorylated tau-217 (p-tau217), and remote disclosure of results by a neurologist? * Is this remote at-home p-tau217 testing workflow acceptable to participants? Participants are adults aged 65 and older who participated in the SHUTi MIND parent study (NCT05565833) and report subjective cognitive concerns or screen positive for possible mild cognitive impairment. Participants will collect a small capillary blood sample at home, return the sample to a central laboratory by overnight shipping for p-tau217 analysis, receive their result during a remote visit with a board-certified neurologist, and complete online surveys at baseline, after results disclosure, and 6 months post-disclosure.

Gender: All

Ages: 65 Years - Any

Updated: 2026-05-19

1 state

Mild Cognitive Impairment (MCI)
Alzheimer's Dementia (AD)
Subjective Cognitive Decline (SCD)
+1